PTC Therapeutics Q4 2022 Earnings Report $50.69 +0.31 (+0.62%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast PTC Therapeutics EPS ResultsActual EPS-$2.35Consensus EPS -$1.96Beat/MissMissed by -$0.39One Year Ago EPS-$2.03PTC Therapeutics Revenue ResultsActual Revenue$167.41 millionExpected Revenue$183.07 millionBeat/MissMissed by -$15.66 millionYoY Revenue Growth+1.30%PTC Therapeutics Announcement DetailsQuarterQ4 2022Date2/21/2023TimeAfter Market ClosesPTCT Upcoming EarningsPTC Therapeutics will be holding an earnings conference call on Thursday, February 27 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingPTCT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by PTC Therapeutics Earnings HeadlinesPTC Therapeutics to Participate in Upcoming Investor ConferencesFebruary 20 at 8:00 AM | prnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $58.85 Consensus Target Price from BrokeragesFebruary 20 at 1:31 AM | americanbankingnews.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?February 22, 2025 | Behind the Markets (Ad)PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's AtaxiaFebruary 19 at 7:00 AM | prnewswire.comRoyal Bank of Canada Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock PriceFebruary 19 at 3:47 AM | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Stock Rating Lowered by StockNews.comFebruary 19 at 1:43 AM | americanbankingnews.comSee More PTC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email. Email Address About PTC TherapeuticsPTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.View PTC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
